Åõ¼®À» ½ÃÀÛÇÏ´Â ¸»±â ½ÅºÎÀüÁõ ȯÀÚ¿¡¼­ Ç÷°ü ³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ»ó
Usefulness of Peritoneal Dialysis (PD) in Patients with Refractory Heart Failure (RHF)

´ëÇѽÅÀåÇÐȸÁö 2006³â 25±Ç 6È£ p.991 ~ p.998

À¯µ¿Àº(Yoo Dong-Eun) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è½ÂÁØ(Kim Seung-Jun) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Ú¼±¿µ(Park Sun-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿ÀÇüÁß(Oh Hyung-Jung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÇѼº(Lee Han-Sung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÁ¤Àº(Lee Jung-Eun) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖÈÆ¿µ(Choi Hoon-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ½ÅÀåÁúȯ ¿¬±¸¼Ò
ÇѽÂÇõ(Han Seung-Hyeok) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇÑ´ë¼®(Han Dae-Suk) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°­½Å¿í(Kang Shin-Wook) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¹è °æ : º¹¸·Åõ¼®Àº ±Þ¼º ¶Ç´Â ¸¸¼º ½ÅºÎÀüÁõ¿¡¼­ ½ÃÇàÇÏ´Â ´ëÇ¥ÀûÀÎ ½Å´ëü¿ä¹ýÀÌÁö¸¸, ¿äµ¶Áõ ÀÌ¿Ü¿¡µµ ÀϹÝÀûÀÎ ¾à¹° Ä¡·á¿¡ È¿°ú°¡ ¾ø´Â ºÒÀÀ¼º ½ÉºÎÀüÁõ ȯÀÚ¿¡¼­ Á¾Á¾ º¸Á¶ ¿ä¹ýÀ¸·Î »ç¿ëµÇ¾î ¿Ô´Ù. ±× °á°ú ȯÀÚÀÇ È°µ¿ ÁöÇ¥°¡ È£ÀüµÇ¾ú´Ù´Â ¸î¸î Áõ·Ê º¸°í´Â ÀÖ¾úÀ¸³ª, ºÒÀÀ¼º ½ÉºÎÀüÁõ ȯÀÚ¿¡¼­ º¹¸·Åõ¼®ÀÇ È¿°ú¸¦ ü°èÀûÀ¸·Î ºÐ¼®ÇÑ ¿¬±¸´Â °ÅÀÇ ¾ø´Â ½ÇÁ¤ÀÌ´Ù. ÀÌ¿¡ ÀúÀÚ µîÀº ¾à¹° ºÒÀÀ¼º ½ÉºÎÀüÁõ ȯÀÚ¸¦ ´ë»óÀ¸·Î º¹¸·Åõ¼®ÀÇ À¯¿ë¼º ¹× È¿°úÀÇ ±âÀü¿¡ ´ëÇÏ¿© ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¹æ ¹ý : 2000³â 1¿ù 1ÀϺÎÅÍ 2005³â 12¿ù 31ÀϱîÁö ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ¼Ó ¼¼ºê¶õ½º º´¿ø ½ÉÀå³»°ú¿¡ ½ÉºÎÀüÁõÀ¸·Î ÀÔ¿øÇÏ¿´´ø ȯÀÚ Áß Ç÷û Å©·¹¾ÆƼ´ÑÀÌ 3.0 mg/dL ¹Ì¸¸ÀÎ »óÅ¿¡¼­ ¾à¹° ºÒÀÀ¼º ½ÉºÎÀüÁõÀ¸·Î ÀÎÇÏ¿© º¹¸·Åõ¼®À» ½ÃÀÛÇÑ È¯ÀÚ 13¸íÀ» ´ë»óÀ¸·Î º¹¸·Åõ¼® ½ÃÇàÀüÈÄÀÇ NYHA class, ½ÉºÎÀüÁõ°ú °ü·ÃµÈ Áõ»óÀ¸·Î ÀÎÇÑ ÀÔ¿ø Ƚ¼ö ¹× Àϼö, ±×¸®°í ½ÉÃÊÀ½ÆÄ ¼Ò°ß µîÀ» ºñ±³ ºÐ¼®ÇÏ¿´´Ù.

°á °ú : º¹¸·Åõ¼®°ü »ðÀÔ ÈÄ ÀÓ»óÀûÀ¸·Î ¾ÈÁ¤È­µÈ »óÅ¿¡¼­ ´ë»óȯÀÚÀÇ Æò±Õ Åõ¼® Ƚ¼ö´Â 2.9¡¾1.0ȸ/ÀÏÀ̾úÀ¸¸ç, º¹¸·Åõ¼®À» ÅëÇÑ Á¦¼ö·®Àº 1ÀÏ Æò±Õ 753.3¡¾280.6 ccÀ̾ú´Ù. NYHA class´Â º¹¸·Åõ¼® ½ÃÇà Àü 3.5¡¾0.5¿¡¼­ º¹¸·Åõ¼® ÈÄ¿¡´Â 2.3¡¾0.9·Î À¯ÀÇÇÏ°Ô È£ÀüµÇ¾úÀ¸¸ç (p<0.005), ½ÉºÎÀüÁõ°ú °ü·ÃµÈ Áõ»óÀ¸·Î ÀÎÇÑ ÀÔ¿ø Ƚ¼ö¿Í Àϼö´Â º¹¸·Åõ¼® Àü °¢°¢ 1.7¡¾0.4ȸ/³â, 62.1¡¾26.5ÀÏ/³â¿¡¼­ º¹¸·Åõ¼® ½ÃÇà ÈÄ¿¡´Â 0.2¡¾0.4ȸ/³â, 3.8¡¾8.9ÀÏ/³âÀ¸·Î ÀǹÌÀÖ°Ô °¨¼ÒµÇ¾ú´Ù (p<0.001). º¹¸·Åõ¼® ÈÄ ½ÉÃÊÀ½ÆÄ ¼Ò°ßÀÇ º¯È­·Î ¿ì½É½Ç¾ÐÀº ÁÂ½É½Ç ºÎÀü ¹× ¿ì½É½Ç ºÎÀü ȯÀÚ ¸ðµÎ¿¡¼­ ÀÇÀÇÀÖ°Ô °¨¼ÒµÇ¾úÀ¸³ª (ÁÂ½É½Ç ºÎÀü, 55.8¡¾27.3 mmHg vs. 36.8¡¾15.2 mmHg, p<0.05; ¿ì½É½Ç ºÎÀü, 95.4¡¾44.0 mmHg vs. 56.0¡¾9.8 mmHg, p<0.05), ÁÂ½É½Ç À̿ϱ⠳»°æÀ̳ª ÁÂ½É½Ç ±¸Ç÷À²¿¡´Â À¯ÀÇÇÑ º¯È­°¡ ¾ø¾ú´Ù. º¹¸·Åõ¼® ½ÃÇà ÈÄ 1³â ȯÀÚ »ýÁ¸À²Àº 75.5%À̾ú´Ù.

°á ·Ð : ºÒÀÀ¼º ½ÉºÎÀüÁõ ȯÀÚ¿¡¼­ º¹¸·Åõ¼®Àº ¿ì½É½Ç¾ÐÀ» °¨¼Ò½ÃÅ´À¸·Î½á ½ÉºÎÀüÁõ°ú °ü·ÃµÈ Áõ»óÀ¸·Î ÀÎÇÑ ÀÔ¿øÀ» °¨¼Ò½Ãų »Ó¸¸ ¾Æ´Ï¶ó »îÀÇ Áúµµ È£Àü½Ãų ¼ö ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ´Ù.
Background : Though PD has served as a treatment method for metabolic derangement in acute or chronic renal failure, it has also been used as a palliative therapy or as a bridge to definite surgery or transplantation in patients with RHF. Some studies have demonstrated that PD reduced hospitalization rates and improved functional capacity in these patients, but changes in echocardiographic findings after PD have not been thoroughly explored. In this study, the effects of PD on hospitalization rates and days, functional status, and echocardiographic parameters were evaluated.

Methods : Thirteen patients, in whom PD was performed to treat heart failure, were enrolled. Patients with serum creatinine levels more than 3.0 mg/dL and with acute cardiac event within 1 month before the start of PD were excluded. The clinical, laboratory, and echocardiographic findings before and after the start of PD were compared by carrying out a paired t-test or Wilcoxon signed rank test.

Results : Among 13 patients, 11 patients experienced improvement in functional status after the initiation of PD, and the mean NYHA class improved from 3.5¡¾0.5 to 2.3¡¾0.9 after PD treatment (p<0.005). Significant reductions in hospitalization rates (from 1.7¡¾0.4 to 0.2¡¾0.4 episodes/patient-year, p<0.001) and in hospitalization days (from 62.1¡¾26.5 to 3.8¡¾8.9 days/patient-year, p<0.001) were also observed since the start of PD. Echocardiographic findings revealed that right ventricular pressure was significantly reduced in both right-sided and left-sided heart failure patients (p<0.05), whereas there were no significant changes in left ventricular end-diastolic diameter and left ventricular ejection fraction after PD therapy.

Conclusion : PD treatment improved quality of life, shortened hospitalization period, and reduced right ventricular pressure in patients with RHF. These findings suggest that PD should be considered as an alternative therapeutic modality for RHF. (Korean J Nephrol 2006;25(6):991-998)

Å°¿öµå

Heart failure, Peritoneal dialysis, Quality of Life, Right ventricular pressure
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
the effects of PD on hospitalization rates and days, functional status, and echocardiographic parameters were evaluated; PD treatment improved quality of life, shortened hospitalization period, and reduced right ventricular pressure in patients with RHF. These findings suggest that PD should be considered as an alternative therapeutic modality for Refractory Heart Failure (RHF).
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå